← FDA DRUG APPROVALS
FDA ANDA · ANDA202996
LARIN 1.5/30
norethindrone acetate/ethinyl estradiol
Sponsor: NOVAST LABS
APPLICATION
ANDA202996
TYPE
ANDA
ORIGINAL APPROVAL
2014-03-20
LATEST ACTION
2024-04-05
ROUTE
ORAL-21
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
LARIN 1.5/30Prescription
ETHINYL ESTRADIOL 0.03MG, NORETHINDRONE ACETATE 1.5MG · TABLET · ORAL-21
Approval history
2024-04-05Labeling · Supplement 9 · standardAP
2024-04-05Labeling · Supplement 10 · standardAP
2024-04-05Labeling · Supplement 2 · standardAP
2014-03-20UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.